RxDoctor Payments Data

Saeed Shaffi, MD

Nephrology · Scottsdale, AZNPI 1952521585

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $14,616 of the $18,714 with a category attached, or 78.1%. Novartis accounts for 97.1% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $7,614 and has fallen 97.2% since, to $217 in 2025. Among nephrology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$18,714in general payments, 2019–2025

Across 26 payments — averaging $719.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$18K
  • Otsuka America Pharmaceutical, Inc.$145
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$127
  • AstraZeneca$122
  • Amgen$122
  • Boehringer Ingelheim$18
  • plus $3 from 1 others
$45,350in research payments, 2019–2025

Across 12 payments — averaging $3779.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$32K
  • Alnylam Pharmaceuticals Inc.$13K

What the payments were for

  • Consulting fees$14,61678%
  • Travel & lodging$2,83215%
  • Food & beverage$1,2667%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,714 in reported general payments places this provider in the 95th percentile of 259 nephrology providers in Arizona.

See all nephrology providers in Arizona

Medicare billing

Part B allowed, 2024
$23,240
Medicare patients
120
Services billed
2,035

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nephrology in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →